Neogen Chemicals Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Neogen Chemicals Ltd filed with BSE on 01 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Neogen Chemicals reported Q1 FY27 consolidated revenue of INR 250 crore, up 34% year-on-year, with EBITDA growing 53% to INR 48 crore and margins expanding to 19.3%, while profit after tax rose 67% to INR 17 crore. Management raised its standalone FY27 revenue guidance from INR 875-950 crore to INR 950-1,050 crore, citing volume growth in organo-lithium, inorganic chemicals, and battery chemicals, and gave updates on the Dahej plant rebuild, insurance recoveries, and Neogen Ionics performance. The company also disclosed board approval for a QIP fundraise of up to INR 600 crore aimed at deleveraging the balance sheet and funding future growth opportunities.
Numbers mentioned
Revenue: INR 250 crore (Q1 FY27)
p. 3
“In Q1 FY27, on a consolidated basis, we recorded revenue of INR 250 crore, registering a robust growth of 34% year-on-year.”
Dr. Harin Kanani, page 3 of the filed PDF · View the filing
EBITDA: INR 48 crore (Q1 FY27)
p. 3
“EBITDA grew by 53% year-on-year to INR 48 crore with EBITDA margins expanding by 260 basis points to 19.3%.”
Dr. Harin Kanani, page 3 of the filed PDF · View the filing
Profit after tax: INR 17 crore (Q1 FY27)
p. 3
“Profit after tax stood at INR 17 crore, surging 67% year-on-year.”
Dr. Harin Kanani, page 3 of the filed PDF · View the filing
Revenue: INR 250 crore (Q1 FY27)
p. 5
“Revenue from operations stood at INR 250 crore, up 34% from INR 187 crore in Q1 FY26.”
Gopikrishnan Sarathy, page 5 of the filed PDF · View the filing
Organic chemicals revenue: INR 194 crore (Q1 FY27)
p. 5
“Across our operational verticals, organic chemicals generated a revenue of INR 194 crore, reflecting an 18% growth, while inorganic chemicals segment delivered a standout performance with a revenue surging 158% to INR 57 crore.”
Gopikrishnan Sarathy, page 5 of the filed PDF · View the filing
Gross profit: INR 117 crore (Q1 FY27)
p. 5
“Gross profit rose by 37% to INR 117 crore, reflecting an optimized product mix and cost pass-through arrangements.”
Gopikrishnan Sarathy, page 5 of the filed PDF · View the filing
EBITDA: INR 48.2 crore (Q1 FY27)
p. 5
“EBITDA stood at INR 48.2 crore, registering a growth of 53% from INR 31.5 crore in Q1 FY26.”
Gopikrishnan Sarathy, page 5 of the filed PDF · View the filing
Depreciation: INR 8.2 crore (Q1 FY27)
p. 5
“Depreciation was higher at INR 8.2 crore, up 42% due to smaller CAPEXes which we had added during the year.”
Gopikrishnan Sarathy, page 5 of the filed PDF · View the filing
Finance cost: INR 20.8 crore (Q1 FY27)
p. 5
“Finance cost stood at INR 20.8 crore, up 64%.”
Gopikrishnan Sarathy, page 5 of the filed PDF · View the filing
PAT margin: 6.8% (Q1 FY27)
p. 5
“Profit after tax reached INR 17.1 crore, growing 67% with PAT margin of 6.8%.”
Gopikrishnan Sarathy, page 5 of the filed PDF · View the filing
Neogen Ionics revenue: INR 19 crore (Q1 FY27)
p. 3
“Neogen Ionics delivered a robust performance in Q1 FY27, generating INR 19 crore in revenue compared to INR 5 crore in Q1 FY26 and delivering over 50% of the entire previous year’s revenue in just three months.”
Dr. Harin Kanani, page 3 of the filed PDF · View the filing
Insurance recoveries to date: INR 164 crore
p. 3
“On the insurance front, cumulative recoveries to date stand at INR 164 crore, which comprises on-account insurance claims as well as salvage realization till now.”
Dr. Harin Kanani, page 3 of the filed PDF · View the filing
Net insurance claim receivable: INR 186 crore
p. 3
“Our net claim receivable as on date stands as INR 186 crore on a consolidated basis and we continue to engage closely with insurers to expedite final settlement against the same”
Dr. Harin Kanani, page 3 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Standalone base business revenue — INR 950 crore to INR 1,050 crore · FY27
stated firmly by Dr. Harin Kanani
p. 4
“we are happy to improve our standalone guidance from INR 875 crore to INR 950 crore to INR 950 crore to INR 1,050 crore in the revised range”
Dr. Harin Kanani, page 4 of the filed PDF · View the filing
Battery chemicals revenue — INR 300 crore · FY27
stated firmly by Dr. Harin Kanani
p. 7
“we are looking at INR 300 crore kind of revenue for the current year for the battery business. We currently maintain the same.”
Dr. Harin Kanani, page 7 of the filed PDF · View the filing
Battery chemicals revenue at full utilization — INR 2,400 crore to INR 2,900 crore · FY29
stated conditionally by Dr. Harin Kanani
p. 6
“the current CAPEX that is undergoing can cater to give us a revenue of around INR 2,400 crore to INR 2,900 crore depending on the lithium prices ongoing and we expect to achieve this by FY29.”
Dr. Harin Kanani, page 6 of the filed PDF · View the filing
Base business revenue — INR 1,100 crore to INR 1,200 crore · FY28
stated as an aspiration by Dr. Harin Kanani
p. 13
“So, we should be somewhere between INR 1,100 crore to INR 1,200 crore in revenue for the next financial year. However, we will give proper guidance closer to the end of the year.”
Dr. Harin Kanani, page 13 of the filed PDF · View the filing
Base business EBITDA margin — 18% plus-minus 1-1.5% · FY27
stated firmly by Dr. Harin Kanani
p. 14
“For EBITDA margin in the current year, our base is 18% plus-minus 1%, 1.5%.”
Dr. Harin Kanani, page 14 of the filed PDF · View the filing
Base business EBITDA margin — 18% to 20% · FY28
stated as an aspiration by Dr. Harin Kanani
p. 14
“next year, depending on how the global macroeconomic (situation) is, we would like to optimize the business a little bit better, and have between 18% to 20% kind of EBITDA margins for the next financial year.”
Dr. Harin Kanani, page 14 of the filed PDF · View the filing
Battery business ROCE — 20% ROCE · FY29
stated as an aspiration by Dr. Harin Kanani
p. 14
“we would maintain 20% ROCE on full utilization levels. So, in FY29, we expect a 20% return on capital on the battery business, which should be around INR 1,800 crore of CAPEX and some working capital requirement.”
Dr. Harin Kanani, page 14 of the filed PDF · View the filing
Salt business utilization — 70%-80% utilization · FY28
stated as an aspiration by Dr. Harin Kanani
p. 15
“we are also targeting in the next financial year around 70%-80% utilization levels for the salt business.”
Dr. Harin Kanani, page 15 of the filed PDF · View the filing
Working capital cycle (base business) — 140 days · FY28
stated as an aspiration by Dr. Harin Kanani
p. 17
“by the time we reach full utilization, let’s say by next financial year, which is FY28, we would be at around 140 days working capital cycle, which is stable”
Dr. Harin Kanani, page 17 of the filed PDF · View the filing
Peak consolidated debt — INR 1,000 to INR 1,500 crore
stated conditionally by Dr. Harin Kanani
p. 17
“Broadly I would say once the INR 600 crore is raised, it should be between INR 1,000 to INR 1,500 like best case-worst case kind of scenario.”
Dr. Harin Kanani, page 17 of the filed PDF · View the filing
Battery chemicals CAPEX completion — INR 1,800 crore · FY27 end
stated firmly by Dr. Harin Kanani
p. 16
“the entire INR 1,800 would be completed by the end of the current financial year”
Dr. Harin Kanani, page 16 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said current capacity targets INR 2,400-2,900 crore by FY29 and that five years out the business mix could be roughly 50-50 between battery and other chemicals, with no dependency on China for technology.
Answered by Dr. Harin Kanani
Asked by Asit Bhandarkar: How big can the battery chemicals opportunity be in five years and what proportion of the business will it represent, given China's restrictions on battery technology?
p. 6
“So, when we are thinking of battery chemicals, Neogen as a policy talks about what revenue guidance we can give based on CAPEX which is currently underway.”
Dr. Harin Kanani, page 6 of the filed PDF · View the filing
Management guided INR 300 crore for battery business in FY27, with roughly INR 200 crore from salt and INR 100 crore from electrolyte, with upside possible from Pakhajan.
Answered by Dr. Harin Kanani
Asked by Arun Prasad: What is the battery chemicals revenue and margin guidance for the current year and how is it split between salt and electrolyte?
p. 7
“we have currently approximately kept around INR 200 crore for the salt and INR 100 crore for the electrolyte.”
Dr. Harin Kanani, page 7 of the filed PDF · View the filing
Management said the QIP will primarily go toward debt reduction and readiness for future growth opportunities, with an estimated INR 40-50 crore annual interest saving if fully repaid.
Answered by Dr. Harin Kanani
Asked by Abhijit Akella: What are the proposed uses of the INR 600 crore QIP and how much will finance costs reduce?
p. 10
“So, may be roughly, if the entire thing is repaid, roughly around INR 40-50 crore for the reduction annually once we settle.”
Dr. Harin Kanani, page 10 of the filed PDF · View the filing
Management confirmed some benefit from selling older inventory but said it was difficult to quantify.
Answered by Dr. Harin Kanani
Asked by Abhijit Akella: Was the Q1 gross margin improvement driven by inventory gains?
p. 12
“Indirectly, in a sense that we had some older inventory but when we were selling it, we got some benefit out of that.”
Dr. Harin Kanani, page 12 of the filed PDF · View the filing
Management said peak debt before the QIP was around INR 1,800 crore net, and could fall to INR 1,000-1,500 crore depending on usage of proceeds and insurance recoveries.
Answered by Dr. Harin Kanani
Asked by Deepak Poddar: What is the peak debt level being targeted after the QIP and other funding sources?
p. 17
“Before the INR 600 crore planned, the peak debt was around INR 1,800 crore net.”
Dr. Harin Kanani, page 17 of the filed PDF · View the filing
Management said FY29 should be the year of full utilization and optimized business leading to better cash flow conversion, though free cash flow will still depend on ongoing capex.
Answered by Dr. Harin Kanani
Asked by Sajal Kapoor: When will EBITDA more consistently convert into operating cash flow given a history of weak conversion?
p. 20
“So, FY29 is where you will have a full year, with an optimized kind of a business.”
Dr. Harin Kanani, page 20 of the filed PDF · View the filing
Management clarified majority of current revenue comes from international electrolyte salt sales, not dependent on PLI, and that PLI delays reflect complexity of cell production rather than a slowdown in the scheme.
Answered by Dr. Harin Kanani
Asked by Namra Shah: What happens to Ionics offtake if ACC PLI customers miss targets or slow production, and is Neogen building a non-PLI customer base?
p. 18
“majority of the revenue is coming from electrolyte salts, which is in the international market. So, currently is not that we are just doing for PLI.”
Dr. Harin Kanani, page 18 of the filed PDF · View the filing
Management said the target is for the majority of demand to eventually be met under contracted pricing tied to lithium carbonate rather than spot pricing, though some interim spot exposure exists.
Answered by Dr. Harin Kanani
Asked by Umang Gada: How does spot pricing for salts affect contracted capacity with customers?
p. 21
“Once we shift to that, hopefully majority of our demand should be met by that. So there is no dependency on the spot market.”
Dr. Harin Kanani, page 21 of the filed PDF · View the filing
Risks flagged
Persistent macro headwinds including geopolitical volatility and uneven end-market demand
p. 2
“The global chemical industry continues to navigate a complex operating landscape characterized by persistent geopolitical volatility, uneven end-market demand, and ongoing redrawing of supply chain dynamics.”
Dr. Harin Kanani, page 2 of the filed PDF · View the filing
Elevated shipping freight costs and temporary overheads from interim toll manufacturing
p. 3
“Our base business demonstrated immense resilience despite ongoing global supply chain volatility, elevated shipping freight costs, and temporary overheads related to interim toll manufacturing arrangements.”
Dr. Harin Kanani, page 3 of the filed PDF · View the filing
Dependence on timing of domestic ACC PLI cell production ramp-up for electrolyte demand
p. 7
“Of course, the electrolyte is subject to Indian ACC PLI exact production, how the plants ramp up and how they start.”
Dr. Harin Kanani, page 7 of the filed PDF · View the filing
Volatility of spot lithium and China pricing affecting near-term salt/electrolyte pricing
p. 8
“the current China spot prices are lower than the formula price.”
Dr. Harin Kanani, page 8 of the filed PDF · View the filing
High working capital intensity due to supply chain inflation and delayed insurance disbursement raising finance costs
p. 5
“The increase in finance cost reflects the higher debt drawdown to fund the ongoing CAPEX at Neogen Ionics, increased working capital intensity due to supply chain inflation and temporary holding costs pending the insurance claim disbursement.”
Gopikrishnan Sarathy, page 5 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.